在心力衰竭中的葡萄糖类-1受体激活剂:机制,证据和确定最佳候选者
Magdy Abdelhamid1, Mostafa M Abdrabou1, Emanuel Faris1
1Department of Cardiology, Faculty of Medicine, Kasr Al Ainy - Cairo University Cairo, Egypt.
Cardiac failure review
|November 14, 2025
概括
类似葡萄糖-1受体激动剂 (GLP-1RAs) 对心力衰竭具有保留喷射分数 (HFpEF) 的益处,特别是在肥胖或糖尿病患者中. 这些药物改善了HFpEF中的体重,症状和HF事件.
科学领域:
- 心脏病学 心脏病学
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 类似葡萄糖-1受体激动剂 (GLP-1RAs) 已成为2型糖尿病和肥胖症的治疗方法.
- GLP-1RAs已经证明了对心血管的好处.
- 保持喷射分数 (HFpEF) 的心力衰竭是一种治疗选择有限的疾病.
研究的目的:
- 评估GLP-1RAs在HFpEF患者中的疗效.
- 探索GLP-1RA在HFpEF中的益处背后的机制.
- 总结目前支持GLP-1RA在HFpEF中的使用的证据.
主要方法:
- 对心血管结局试验和专门的HFpEF试验的审查.
- 分析包括减肥,降血压,血糖控制和抗炎作用在内的机制.
- 对直接心脏保护和血管作用的评估.
主要成果:
- GLP-1RAs在HFpEF患者中表现出有效性,特别是那些患有肥胖和/或糖尿病的患者.
- 在一些试验中观察到体重,HF症状和HF事件的显著改善.
- 机制包括减肥,改善血糖控制,减少炎症和潜在的直接心脏益处.
结论:
- 目前的证据强烈支持GLP-1RAs在患有HFpEF和肥胖,有或没有2型糖尿病的患者中使用.
- GLP-1RAs通过多个途径为HFpEF患者提供显著的好处.
- 数据不支持使用GLP-1RAs仅用于心力衰竭与减少喷射率 (HFrEF).
相关概念视频
01:24Glucagon-like Receptor Agonists
828
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
828
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
902
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
902
01:27Transducer Mechanism: Enzyme-Linked Receptors
3.8K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
3.8K
01:30Heart Failure V: Medical Management
207
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
207
01:26Heart Failure Drugs: Inotropic Agents
1.2K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.2K
01:29Heart Failure II: Pathophysiology
695
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
695